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Philadelphia (Ph) chromosome (9;22)(q34;q11) is well established in more than 90% 
of chronic myeloid leukemia (CML) patients, and the remaining 5–8% of CML patients 
show variant and complex translocations, with the involvement of third, fourth, or fifth 
chromosome other than 9;22. However, in very rare cases, the fourth chromosome is 
involved. Here, we found a novel case of four-way Ph+ chromosome translocation involv-
ing 46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2) with CML in the chronic phase. Complete 
blood cell count of the CML patient was carried out to obtain total leukocytes count, 
hemoglobin, and platelets. Fluorescence in  situ hybridization technique was used for 
the identification of BCR–ABL fusion gene, and cytogenetic test for the confirmation of 
Ph (9;22)(q34;q11) and the mechanism of variant translocation in the bone marrow. The 
patient is successfully treated with a dose of 400 mg/day imatinib mesylate (Gleevec). We 
observed a significant decrease in white blood cell count of 11.7 × 109/L after 48-month 
follow-up. Patient started feeling better generally. There was a reduction in the swelling 
of the body, fatigue, and anxiety.
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FIGURe 1 | Cytogenetic analysis shows the karyotype of the CML patient with 46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2). All derivative chromosomes are 
highlighted by arrow heads.
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INtRoDUCtIoN
Chronic myeloid leukemia (CML) is triggered due to the t(9;22)
(q34;q11) translocation between the long arms of chromosomes 9 
and 22, called as the Philadelphia (Ph) chromosome (1). In these 
patients, bone marrow myeloid hyperplasia, an elevated myeloid 
and erythroid cells, and platelets in the peripheral blood were 
observed (2). This translocation was identified in more than 90% 
of the CML patients (3, 4), and the variant/complex translocation 
was observed in 5–8% of cases with an involvement of additional 
third, fourth, or fifth chromosome (5–7).
The imatinib mesylate is commonly used as the first-line oral 
treatment of CML patients (6). It blocks the BCR–ABL tyrosine 
kinase activity and subsequently induces apoptosis followed by 
the reduction in the proliferation of BCR–ABL-expressing cells in 
both CML and acute lymphocytic leukemia (ALL). The treatment 
of CML patients with imatinib significantly increased the survival 
and improved the quality of life (8).
Potentially imatinib meysylate inhibits the BCR/ABL and 
platelet-derived growth factor receptor (PDGFR) tyrosine kinase 
activities. This deactivates downstream signaling by reducing 
cell proliferation and augmenting apoptosis. Imatinib mesylate 
(Gleevec) therapy has significantly increased the efficacy in 
0–34% of Ph-positive cells with t(9;22) translocation along with 
other complex translocations causing BCR/ABL gene fusion and 
subsequent clonal evolution (9, 10). In this study, for the first 
time, we present a four-way Ph translocation 46,XY,t(4;9;19;22)
(q25:q34;p13.3;q11.2) in a CML patient with a new complex rear-
rangement between chromosomes 4 and 19 as well as 9 and 22.
Report
A 45-year-old male patient was diagnosed with CML on 19 October, 
2012. The hematological parameters were hemoglobin (Hb) 
10.0  g/dL (normal range, 14–18  mg/dL), MCV 59.6  fL (normal 
range, 76–95 fL), MCH 19 pg (normal range, 27–32 pg), MCHC 
31.9% (normal range, 30–35), hematocrit 31.4% (normal range, 
40–54%), red blood cell (RBC) 5.26 × 109/L (normal range, 4.5–
6.5 × 109/L), white blood cell (WBC) 160.7 × 109/L (normal range, 
4–11 × 103/μL × 109/L), neutrophils 58% (normal range, 40–75%), 
lymphocytes 2% (normal range, 20–45), eosinophils 3% (normal 
range, 1–6%), monocytes 4% (normal range, 2–10%), basophils 4% 
(normal range, 0–1%), metamyelocytes 15% (normal range, 0–0%), 
myelocytes 15% (normal range, 0–0%), blast cells 2% (normal range, 
0–0%), and platelets 223 × 109/L (normal range, 150–400 × 109/L). 
Peripheral film showed dimorphic picture, anisocytosis, hypochro-
mic, microcytic, polychromasia, polychromasia, tear drop cells, 
and nucleated RBC. A written informed ethical consent was taken 
from the patient before the study according to Helsinki declaration. 
The ethical committee of Balochistan University of Information 
Technology, Engineering and Management Sciences (BUITEMS), 
Quetta, Pakistan, had given the approval for this study.
MateRIaLs aND MetHoDs
Complete Blood Count Laboratory test
Complete blood count (CBC) was performed to measure the levels 
of WBCs, RBCs, Hb, and platelets in the CML patients. CBC was 
performed using an Automatic Hematological Analyzer (Nihon 
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Khoden, Japan) within 2  h of blood sampling. An increase in 
WBCs and lower levels of RBCs and platelets confirmed the leuke-
mia, and these patients were considered for further examination.
Cytogenetic analysis
Chromosome analysis using GTG banding was done as 
described previously (9). Karyotyping was performed in 25 
metaphases from unstimulated bone marrow samples accord-
ing to the nomenclature of the International System for Human 
Cytogenetics (11).
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization was performed to detect BCR/
ABL as described previously (12).
ResULts
The cytogenetic analysis showed 46,XY,t(4;9)(q25:q34)t(9;22)
(q34;q11.2). Twenty-five cells were counted, and all were positive 
for Ph chromosome (Figure 1).
The BCR–ABL translocation was detected by fluorescence 
in  situ hybridization (FISH) analysis in 91% of the 500 nuclei 
counted. In this study, FISH analysis of the ABL (9q34) gene was 
identified by fluorescent red dots and BCR (22q11) gene by green 
dots. Therefore, a cell exhibiting two separate green and red dots 
counted as a normal cell shows no translocation. However, the 
irregular translocation in a cell was identified by one red and 
one green and fused red, yellow, and green signal. Dual color, 
dual fusion translocation probes were hybridized to patient’s 
interphase nuclei (Figure 2).
Clinical analysis shows the induced level of WBC (160.7 × 
109/L) and low level of Hb (10 mg/dL), which indicates anemia 
in the CML patient.
The X-ray analysis studies showed no active pulmonary 
or pleural lesion, normal cardiac and aorta, normal hilar and 
mediastinal shadows, normal costophrenic angles, normal domes 
of diaphragm, and normal bony thoracic cage with the normal 
finding in the chest study. The analysis of liver showed a slight 
enlargement in size, whereas spleen was massively enlarged, with 
normal gallbladder, pancreas, kidneys, and retroperitoneum with 
mild hepatomegaly.
HBsAg and anti-HCV tests were performed by an immu-
nochromatographic screening method, which showed negative 
results. The patient was treated with antibiotics and Gleevec 
(imatinib mesylate) 400  mg/day. Socioeconomic status of the 
CML patient was middle class, and he was aware of this disease.
DIsCUssIoN
Chronic myeloid leukemia is primarily caused by the balanced 
translocation between the long arms of 9;22 chromosomes and 
secondarily by the variant and complex translocation patients. 
FIGURe 2 | Fluorescence in situ hybridization (FIsH) for the detection of (9;22)(q34;q11). BCR–ABL translocation was detected in 91% of the 500 nuclei 
counted.
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taBLe 1 | Number of complex variant four-way ph chromosome 
translocations reported in the literature.






























































In such cases, the third, fourth, or even fifth chromosome 
was involved and is termed as four-, five-, or six-way trans-
location (6). The four-way translocation is rare; only 59 cases 
are reported in the literature. The four-way translocation is 
observed more in male than in female. The five-way transloca-
tion is very rare in the CML patients, with only few cases are 
on record (Table 1).
In this study, we reported this new four-way translocation 
46,XY,t(4;9;19;22)(q25:q34;p13.3;q11.2) in a CML patient for 
the first time and was cross-checked in Mitelman Database 
of Chromosome Aberrations and Gene Fusions in Cancer. 
In four-way Ph chromosome translocation, male patients 
are 46-XY,t(56%) who are more affected compared to female 
patients who are 46-XX,t(39%) (Figure 3), whereas in addition 
to chromosome 9;22, chromosome 4 (2%) is least compared to 
chromosome 19, 12, 6 (9%) in four-way Ph chromosome translo-
cation (Figure 3). BCR–ABL translocation was detected in 91% 
of the 500 nuclei counted. Dual color, dual fusion translocation 
probes were hybridized to patient’s interphase nuclei. Normal 
nuclei lacking the t(9;22) translocation showed two green and 
two orange signals. In the nucleus containing a simple balanced 
t(9;22), one green and one orange signal from the normal 9 and 
22 chromosomes and two green/orange (yellow) fusion signals, 
one each from the chromosomes 9 and 22.
Mkrtchyan et al. have described two sustainable mechanisms 
for the formation of variant complex translocation, namely, a 
single incident rearrangement via the simultaneous breakage 
of few chromosomes followed by mismatched joining and a 
multistep process of classical Ph translocation followed by addi-
tional translocations in chromosomes 9 and 22, as well as other 
chromosomes (49).
Imatinib mesylate (Gleevec) potentially inhibits BCR–ABL 
protein tyrosine kinase. Furthermore, it inhibits the tyrosine 
FIGURe 3 | percentage of four-way complex variant translocation in 
male and female CML patients.
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kinase activities of the platelet-derived growth factor (PDGF) 
receptor β and c-Kit, but it does not inhibit Flt-3 and Fms 
belonging to type III tyrosine kinase family (50, 51). Being a 
first-line oral therapy, imatinib mesylate, an inhibitor of tyros-
ine kinase activity of BCR–ABL protein, is recommended for 
Ph-positive chromosome-associated abnormalities. Hence, it 
would be useful in three-way, four-way, and five-way complex 
variant translocations, as reported earlier by other research 
groups (6, 21).
Finally, a unique case of four-way complex variant Ph-positive 
translocation involving chromosome 46,XY,t(4;9;19;22)
(q25:q34;p13.3;q11.2) in a CML patient was reported in this 
study.
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